Expert Opinion on Biological Therapy

Papers
(The H4-Index of Expert Opinion on Biological Therapy is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives90
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)45
Bispecific antibodies for the treatment of hemophilia A44
Biologic therapies for chronic obstructive pulmonary disease43
Bispecific antibodies for immune cell retargeting against cancer40
The potential for medical therapies to address fistulizing Crohn’s disease: a state-of-the-art review34
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents33
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial33
Biological therapies for the treatment of psoriasis in pediatrics31
The history of Crohn’s perianal fistula treatment with mesenchymal stem cells: the story of darvadstrocel30
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer29
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study29
The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?28
Small molecule-regulated switches to provide functional control of CAR T cells within the patient27
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies27
Mosunetuzumab for the treatment of follicular lymphoma27
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective25
Cell-based therapies for the treatment of sports injuries of the upper limb25
Emerging therapies for human hearing loss24
Elotuzumab in multiple myeloma24
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era24
Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men23
0.17736291885376